Research statistics
Maridebart cafraglutide research: publications and trials
At a glance
Publications, all years
11
Since 2024
Publications in 2026 so far
3
Through November 15, 2026
Human clinical research
18.2%
2 of 11 classified
Registered clinical trials
32
ClinicalTrials.gov
Randomized controlled trials
2
Publications reporting an RCT in people
Systematic reviews and meta-analyses
0
Preclinical studies
9.1%
1 animal · 0 in vitro · 0 computational
Records that only mention it
18
Not counted above
Status in the library: In clinical trials. Groups: GLP-1 receptor agonists.
What to keep in mind
- Fewer than three randomized controlled trials are indexed.
- Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Maridebart cafraglutide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2024 | 1 | 0 | 0 | 2 | 3 |
| 2025 | 1 | 0 | 1 | 3 | 5 |
| 2026 (to date) | 0 | 1 | 2 | 0 | 3 |
Study types
| Editorial, letter or other | 5 |
|---|---|
| Review | 3 |
| Randomized controlled trial | 2 |
| Animal study | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Obesity and weight management | 7 |
|---|---|
| Metabolic health | 6 |
| Endocrinology | 2 |
| Antimicrobial and infectious disease | 1 |
| Immune system | 1 |
| Neurological and mental health | 1 |
| Oncology | 1 |
Registered clinical trials
5 of 7 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 13 · Active, not recruiting: 10 · Recruiting: 7 · Not yet recruiting: 2
Phase 1: 17 · Phase 2: 3 · Phase 3: 12
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
The New England journal of medicine · June 23, 2025 · Randomized controlled trial · cited 105 times
PMID 40549887 · DOI 10.1056/nejmoa2504214 · Human clinical research
- A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.
Nature metabolism · February 5, 2024 · Randomized controlled trial · cited 216 times · open access
PMID 38316982 · DOI 10.1038/s42255-023-00966-w · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.
Nature metabolism · February 5, 2024 · Randomized controlled trial · cited 216 times · open access
PMID 38316982 · DOI 10.1038/s42255-023-00966-w · Human clinical research
- Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
The New England journal of medicine · June 23, 2025 · Randomized controlled trial · cited 105 times
PMID 40549887 · DOI 10.1056/nejmoa2504214 · Human clinical research
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
Endocrine reviews · March 1, 2026 · Review · cited 37 times
PMID 41054801 · DOI 10.1210/endrev/bnaf036 · Reviews and meta-analyses
- The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs.
Journal of clinical medicine · May 29, 2025 · Review · cited 12 times · open access
PMID 40507574 · DOI 10.3390/jcm14113812 · Reviews and meta-analyses
- Antagonizing GIPR adds fire to the GLP-1R flame.
Trends in endocrinology and metabolism: TEM · May 18, 2024 · Editorial, letter or other · cited 11 times · open access
PMID 38763780 · DOI 10.1016/j.tem.2024.04.016 · Commentary and other
Latest publications
- Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.
Antibody therapeutics · June 1, 2026 · Review · cited 1 times · open access
PMID 42592044 · DOI 10.1093/abt/tbag029 · Reviews and meta-analyses
- Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity.
Journal of medicinal chemistry · April 6, 2026 · Animal study · cited 3 times · open access
PMID 41941715 · DOI 10.1021/acs.jmedchem.6c00032 · Animal studies
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
Endocrine reviews · March 1, 2026 · Review · cited 37 times
PMID 41054801 · DOI 10.1210/endrev/bnaf036 · Reviews and meta-analyses
- Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.
The New England journal of medicine · December 1, 2025 · Editorial, letter or other · cited 1 times
PMID 41337722 · DOI 10.1056/nejmc2514331 · Commentary and other
- Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply.
The New England journal of medicine · December 1, 2025 · Editorial, letter or other · cited 2 times
PMID 41337724 · DOI 10.1056/nejmc2514331 · Commentary and other
- Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.
The New England journal of medicine · December 1, 2025 · Editorial, letter or other · cited 0 times
PMID 41337723 · DOI 10.1056/nejmc2514331 · Commentary and other
- Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
The New England journal of medicine · June 23, 2025 · Randomized controlled trial · cited 105 times
PMID 40549887 · DOI 10.1056/nejmoa2504214 · Human clinical research
- The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs.
Journal of clinical medicine · May 29, 2025 · Review · cited 12 times · open access
PMID 40507574 · DOI 10.3390/jcm14113812 · Reviews and meta-analyses
- Antagonizing GIPR adds fire to the GLP-1R flame.
Trends in endocrinology and metabolism: TEM · May 18, 2024 · Editorial, letter or other · cited 11 times · open access
PMID 38763780 · DOI 10.1016/j.tem.2024.04.016 · Commentary and other
- Phase I results for AMG 133.
Nature reviews. Endocrinology · April 1, 2024 · Editorial, letter or other · cited 6 times
PMID 38388678 · DOI 10.1038/s41574-024-00967-z · Commentary and other
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: AMG 133; Maridebart cafraglutide; MariTide
((TITLE_ABS:"AMG 133" OR CHEM:"AMG 133" OR TITLE_ABS:"AMG133" OR CHEM:"AMG133") OR (TITLE_ABS:"Maridebart cafraglutide" OR CHEM:"Maridebart cafraglutide") OR (TITLE_ABS:"MariTide" OR CHEM:"MariTide")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Maridebart cafraglutide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/maridebart-cafraglutide